Article · 17 Jun 2024
CommentaryPublished 27 Oct 2021
Critical Differences in Generics and Biosimilars
Keywords
Subjects
Pharmaceutical SciencesSimilar by topic
Conference abstract · 7 Nov 2016
Why are not biosimilars generics-regulatory challenges?
Conference abstract · 8 Sep 2014
Why aren’t biosimilars generics - regulatory challenges
Conference abstract · 26 Oct 2015
Cost- Effective clinical trial design to detect immunogenicity and efficacy differences between biosimilar and innovator product.
Conference abstract · 2017
Effect of manufacturing process and container closure configurations on critical quality attributes of generic parenteral drug product: A case study of pH
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Richard Dang”

